Health insurers must make educated guesses on 2015 prices
The back-loaded enrollment process for the Obamacare exchanges gives insurers far, far less information about their new customers than usual.
Health Care & Life Sciences
Articles
Five things I learned from the Medicare doctor payments
From this week’s historic data dump, I learned who the top 20 recipients of Medicare payments are in Indianapolis (hint: mostly labs, ambulances and eye surgeons). But the real takeaway is that meaningful price information about doctors is still a long way away.
Indiana insurers must make best guesses on 2015 price hikes
Health insurers such as WellPoint Inc. that plan to hike prices on their Obamacare policies more than 10 percent in 2015 will have a much harder time than usual making their case to regulators.
WellPoint spending millions in California ballot battle
WellPoint Inc. is leading companies that have poured $13.4 million into defeating a ballot initiative that would give California regulators the power to reject increases in health policy premiums.
Lilly stock shows little impact from $3B court award
Eli Lilly and Co.’s stock showed little change Tuesday morning in the wake of a federal court decision that saw jurors order the company to pay a massive damage award related to its Actos diabetes medicine.
Ex-owner of troubled dental clinic pleads guilty to tax evasion
The former owner of a central Indiana dental clinic being investigated for Medicaid fraud has been sentenced to two years in federal prison for not paying more than $850,000 in taxes.
Lilly ordered to pay $3 billion in Actos damages
Takeda Pharmaceutical Co. and Eli Lilly and Co. were ordered to pay a combined $9 billion after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S. trial of its kind.
Lilly shares hit all-time high for the John Lechleiter era
Court win last week in a patent challenge to lung cancer drug Alimta pushed Lilly shares higher than they’ve ever been since April 2007. Since then, the company’s pipeline has produced more misfires than the villains in a James Bond movie
Endocyte raises another $100M in stock offering
Another public stock offering by the West Lafayette-based drugmaker swells its war chest for cancer drug development to $225 million.
Pfizer, Lilly drugs slow advanced breast cancer in studies
Pfizer Inc., Eli Lilly and Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential.
Hospitals might chip in to expand Medicaid
If Indiana hospitals want an expansion of insurance coverage for low-income Hoosiers, Gov. Mike Pence thinks they should contribute toward the hundreds of millions of dollars it would cost.
IU Health doctors to do surgeries in Wisconsin
Indiana University Health was chosen by a hospital system in Wisconsin to provide heart, lung, esophagus and aorta surgeries there after the surgeons the hospital system had been using became employed by a competing provider.
The Millionaire Doctors Club
The scramble for physicians by hospitals in recent years has led to more than a dozen physicians cracking a million dollars in compensation—and three dozen receiving at least a half million dollars. Hospitals, meanwhile, are recording big losses on their physician practices.
UPDATE: Nine at dental practice charged in fraud probe
Prosecutors have charged the owner of an Anderson dental practice and eight of her employees in connection with a Medicaid fraud investigation.
Big health care insurers bulk up executive pay
WellPoint CEO Joe Swedish wasn’t the only health insurance exec making big bucks last year. Aetna Inc. Chairman and CEO Mark T. Bertolini saw his total compensation more than double, to top $30 million.
CarDon trying to adjust nursing homes to hospitals, insurers, patients
Family-run company is building nursing homes it thinks will be more attractive to residents and staff.
Patent ‘troll’ label gets Congress to ponder what’s in a name
“Troll” is a term without clear definition and yet it’s being used to push Congress and the Supreme Court to curb abusive litigation. Companies including Eli Lilly warn against damaging a centuries-old system designed to promote advances in science and industry.
Would-be Lilly foe wins U.S. panel backing for inhaled insulin
Advisers to the Food and Drug Administration voted 13-1 and 14-0 that the drug, Afrezza, should be approved for Type 1 and Type 2 diabetes, respectively. The FDA doesn’t have to follow the panel’s recommendation.
Indianapolis court backs patent for Lilly cancer drug Alimta
A federal court has upheld the patent that protects Eli Lilly and Co.'s lung-cancer treatment from generic competition until 2022.
Pence continues to seek repeal of medical device tax
A number of Indiana lawmakers – including both of the state’s U.S. senators – have advocated for the elimination of the tax, in part because the state is home to several key medical device manufacturers.